157 related articles for article (PubMed ID: 34065481)
1. An SPRi Biosensor for Determination of the Ovarian Cancer Marker HE4 in Human Plasma.
Szymanska B; Lukaszewski Z; Zelazowska-Rutkowska B; Hermanowicz-Szamatowicz K; Gorodkiewicz E
Sensors (Basel); 2021 May; 21(10):. PubMed ID: 34065481
[TBL] [Abstract][Full Text] [Related]
2. A Multiple-Array SPRi Biosensor as a Tool for Detection of Gynecological-Oncological Diseases.
Szymanska B; Lukaszewski Z; Hermanowicz-Szamatowicz K; Gorodkiewicz E
Biosensors (Basel); 2023 Feb; 13(2):. PubMed ID: 36832045
[TBL] [Abstract][Full Text] [Related]
3. Detection of serum human epididymis secretory protein 4 in patients with ovarian cancer using a label-free biosensor based on localized surface plasmon resonance.
Yuan J; Duan R; Yang H; Luo X; Xi M
Int J Nanomedicine; 2012; 7():2921-8. PubMed ID: 22745553
[TBL] [Abstract][Full Text] [Related]
4. Two SPRi biosensors for the determination of cathepsin S in blood plasma.
Oldak L; Sankiewicz A; Żelazowska-Rutkowska B; Cylwik B; Lukaszewski Z; Skoczylas M; Gorodkiewicz E
Talanta; 2021 Apr; 225():121900. PubMed ID: 33592693
[TBL] [Abstract][Full Text] [Related]
5. Electrochemical immunomagnetic assay as biosensing strategy for determination of ovarian cancer antigen HE4 in human serum.
Mattarozzi M; Giannetto M; Careri M
Talanta; 2020 Sep; 217():120991. PubMed ID: 32498877
[TBL] [Abstract][Full Text] [Related]
6. An Immunosensor for the Determination of Cathepsin S in Blood Plasma by Array SPRi-A Comparison of Analytical Properties of Silver-Gold and Pure Gold Chips.
Falkowski P; Mrozek P; Lukaszewski Z; Oldak L; Gorodkiewicz E
Biosensors (Basel); 2021 Aug; 11(9):. PubMed ID: 34562888
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
8. Two Biosensors for the Determination of Interleukin-6 in Blood Plasma by Array SPRi.
Szymanska B; Lukaszewski Z; Oldak L; Zelazowska-Rutkowska B; Hermanowicz-Szamatowicz K; Gorodkiewicz E
Biosensors (Basel); 2022 Jun; 12(6):. PubMed ID: 35735559
[TBL] [Abstract][Full Text] [Related]
9. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
Dewan R; Dewan A; Jindal M; Bhardawaj M
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
[TBL] [Abstract][Full Text] [Related]
11. Two Biosensors for the Determination of VEGF-R2 in Plasma by Array SPRi.
Oldak L; Zelazowska-Rutkowska B; Lesniewska A; Mrozek P; Skoczylas M; Lukaszewski Z; Gorodkiewicz E
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615347
[TBL] [Abstract][Full Text] [Related]
12. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
14. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
Li W; Wang D
Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
[TBL] [Abstract][Full Text] [Related]
15. A biosensor for determination of the circulating biomarker CA125/MUC16 by Surface Plasmon Resonance Imaging.
Szymańska B; Lukaszewski Z; Hermanowicz-Szamatowicz K; Gorodkiewicz E
Talanta; 2020 Jan; 206():120187. PubMed ID: 31514860
[TBL] [Abstract][Full Text] [Related]
16. An Array SPRi Biosensor for the Determination on PARP-1 in Blood Plasma.
Zielinska Z; Oldak L; Kacperczyk-Bartnik J; Koc-Żórawska E; Żórawski M; Laudanski P; Gorodkiewicz E
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831138
[TBL] [Abstract][Full Text] [Related]
17. Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site.
Celik B; Bulut T; Yalcin AD
Pathol Oncol Res; 2020 Apr; 26(2):1145-1151. PubMed ID: 31165997
[TBL] [Abstract][Full Text] [Related]
18. Human Epididymis Protein 4 (HE4) Reference Limits in Polish Population of Healthy Women, Pregnant Women, and Women with Benign Ovarian Tumors.
Gasiorowska E; Kluz T; Lipski D; Warchoł W; Tykarski A; Nowak-Markwitz E
Dis Markers; 2019; 2019():3890906. PubMed ID: 31583027
[TBL] [Abstract][Full Text] [Related]
19. Human epididymis protein 4 reference intervals in a multiethnic asian women population.
Mokhtar N; Thevarajah M; Ma N; M I
Asian Pac J Cancer Prev; 2012; 13(12):6391-5. PubMed ID: 23464464
[TBL] [Abstract][Full Text] [Related]
20. Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics.
Lycke M; Ulfenborg B; Malchau Lauesgaard J; Kristjansdottir B; Sundfeldt K
Clin Chem Lab Med; 2021 Nov; 59(12):1954-1962. PubMed ID: 34388324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
